Sage Therapeutics, Inc.
|Company Name||Sage Therapeutics, Inc.|
The Firm announces an investigation on behalf of investors of Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
On March 23, 2016, Kerrisdale Capital published a report on the Company, alleging that the Company’s drug, SAGE-547, aimed at treating a condition called super-refractory status epilepticus (“SRSE”) “is little more than a Band-Aid, achieving, at best, a temporary reduction in brain activity – very similar to many other treatments that doctors already use.” In addition, the report claims that “Sage’s estimates of the size of the SRSE market are inflated by a factor of 6,” which raises questions regarding the drug’s commercial prospects even if the drug is eventually approved.
On this news, Sage shares fell nearly 20% during intra-day trading on March 23, 2016, on unusually high volume, thereby injuring investors.
If you purchased Sage securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to email@example.com.
Submit Your Information
If you suffered a loss on your Sage Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.
An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.